Daniel P. Petrylak
About
Daniel P. Petrylak is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Daniel P. Petrylak has authored 529 papers receiving a total of 23.1k indexed citations (citations by other indexed papers that have themselves been cited), including 297 papers in Pulmonary and Respiratory Medicine, 280 papers in Oncology and 232 papers in Surgery. Recurrent topics in Daniel P. Petrylak's work include Prostate Cancer Treatment and Research (234 papers), Bladder and Urothelial Cancer Treatments (224 papers) and Cancer Immunotherapy and Biomarkers (162 papers). Daniel P. Petrylak is often cited by papers focused on Prostate Cancer Treatment and Research (234 papers), Bladder and Urothelial Cancer Treatments (224 papers) and Cancer Immunotherapy and Biomarkers (162 papers). Daniel P. Petrylak collaborates with scholars based in United States, France and United Kingdom. Daniel P. Petrylak's co-authors include Joaquim Bellmunt, Maha Hussain, Mitchell C. Benson, Nicholas J. Vogelzang, Yohann Loriot, E. David Crawford, Eric J. Small, Primo N. Lara, Catherine M. Tangen and Patrick A. Burch and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Biological Chemistry.
In The Last Decade
Daniel P. Petrylak
510 papers receiving 22.7k citations
Hit Papers
Peers
Daniel P. Petrylak
Ronald de Wit Netherlands
Joaquim Bellmunt United States
Joel Picus United States
Cora N. Sternberg United States
Walter M. Stadler United States
Allan T. van Oosterom Belgium
J. Wanders Netherlands
Filippo de Braud Italy
Jacek Jassem Poland
Derek Raghavan United States
Citations per year, relative to Daniel P. Petrylak Daniel P. Petrylak (= 1×)
peers
Ronald de Wit
Countries citing papers authored by Daniel P. Petrylak
Since
Specialization
Citations
This map shows the geographic impact of Daniel P. Petrylak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel P. Petrylak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel P. Petrylak more than expected).
Fields of papers citing papers by Daniel P. Petrylak
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniel P. Petrylak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel P. Petrylak. The network helps show where Daniel P. Petrylak may publish in the future.
Co-authorship network of co-authors of Daniel P. Petrylak
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel P. Petrylak. A scholar is included among the top collaborators of Daniel P. Petrylak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel P. Petrylak. Daniel P. Petrylak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gupta, Shilpa, Miguel Á. Climent Durán, Howard Gurney, et al.. (2025). Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients. ESMO Open. 10(4). 104506–104506.
2.
Friedlander, Terence W., Peter H. O’Donnell, Daniel P. Petrylak, et al.. (2025). 3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y. Annals of Oncology. 36. S1487–S1488.
3.
Loriot, Yohann, Arlene O. Siefker‐Radtke, Terence W. Friedlander, et al.. (2025). A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).. Journal of Clinical Oncology. 43(5_suppl).
4.
Loriot, Yohann, Arlene O. Siefker‐Radtke, Terence W. Friedlander, et al.. (2024). A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.. Journal of Clinical Oncology. 42(16_suppl). TPS4619–TPS4619.
5.
Bellmunt, Joaquim, Thomas Powles, Se Hoon Park, et al.. (2024). Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden.. Journal of Clinical Oncology. 42(16_suppl). 4566–4566.
6.
Antonarakis, Emmanuel S., Sumit K. Subudhi, Christopher Pieczonka, et al.. (2023). Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical Cancer Research. 29(13). 2426–2434.
7.
Halabi, Susan, Qian Yang, Bin Luo, et al.. (2023). External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 41(15). 2736–2746.
8.
Petrylak, Daniel P., Bernhard J. Eigl, Saby George, et al.. (2023). Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(1). 63–73.
9.
Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2023). A Plain Language Summary Exploring a New Treatment Combination for Untreated Locally Advanced or Metastatic Urothelial Cancer: Enfortumab Vedotin Plus Pembrolizumab. Future Oncology. 20(7). 351–360.
10.
Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2022). Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of Clinical Oncology. 41(1). 22–31.
11.
Petrylak, Daniel P., Yohann Loriot, David R. Shaffer, et al.. (2021). Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research. 27(12). 3360–3369.
12.
Bono, Johann S. de, Mark T. Fleming, Judy S. Wang, et al.. (2021). Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clinical Cancer Research. 27(13). 3602–3609.
13.
Fong, Lawrence, Michael J. Morris, Oliver Sartor, et al.. (2021). A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 27(17). 4746–4756.
14.
Powles, Thomas, Srikala S. Sridhar, Yohann Loriot, et al.. (2021). Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nature Medicine. 27(12). 2200–2211.
15.
Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2020). EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology. 38(10). 1041–1049.
16.
Grivas, Petros, Cora N. Sternberg, Neeraj Agarwal, et al.. (2020). 796TiP TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) and pembrolizumab (pembro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)-based therapy. Annals of Oncology. 31. S604–S605.
17.
Antonarakis, Emmanuel S., Eric J. Small, Daniel P. Petrylak, et al.. (2018). Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research. 24(19). 4662–4671.
18.
Bellmunt, Joaquim, Ronald de Wit, David J. Vaughn, et al.. (2017). Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine. 376(11). 1015–1026.
19.
Mohile, Supriya G., Kathryn Bylow, William Dale, et al.. (2007). A pilot study of the vulnerable elders survey‐13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 109(4). 802–810.
20.
Goldberg, Jonathan S., Matthew I. Milowsky, Lorraine J. Gudas, et al.. (2002). Phase I trial of interferon α2b and liposome‐encapsulated all‐trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer. 95(6). 1220–1227.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ronald de Wit Breakdown of academic impact, for papers by Joaquim Bellmunt Breakdown of academic impact, for papers by Joel Picus Breakdown of academic impact, for papers by Cora N. Sternberg Breakdown of academic impact, for papers by Walter M. Stadler Breakdown of academic impact, for papers by Allan T. van Oosterom Breakdown of academic impact, for papers by J. Wanders Breakdown of academic impact, for papers by Filippo de Braud Breakdown of academic impact, for papers by Jacek Jassem Breakdown of academic impact, for papers by Derek Raghavan